npj Vaccines (Jun 2023)

Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types

  • Ming-Shu Hsieh,
  • Mei-Yu Chen,
  • Chia-Wei Hsu,
  • Yu-Wen Tsai,
  • Fang-Feng Chiu,
  • Cheng-Lung Hsu,
  • Chang-Ling Lin,
  • Chiao-Chieh Wu,
  • Ling-Ling Tu,
  • Chen-Yi Chiang,
  • Shih-Jen Liu,
  • Ching-Len Liao,
  • Hsin-Wei Chen

DOI
https://doi.org/10.1038/s41541-023-00680-4
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects.